natalizumab-sztn Tyruko
Selected indexed studies
- PB006: A Natalizumab Biosimilar. (Clin Drug Investig, 2024) [PMID:38683493]
- A comparison of JC virus assay performance provided with originator and biosimilar natalizumab. (Mult Scler, 2025) [PMID:40515643]
- Approach to JCV testing with natalizumab biosimilar: a UK consensus statement. (Mult Scler Relat Disord, 2025) [PMID:40460616]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- PB006: A Natalizumab Biosimilar. (2024) pubmed
- A comparison of JC virus assay performance provided with originator and biosimilar natalizumab. (2025) pubmed
- Approach to JCV testing with natalizumab biosimilar: a UK consensus statement. (2025) pubmed
- Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial. (2023) pubmed
- Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab. (2024) pubmed
- Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment. (2026) pubmed